Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline
- Financing led by TCGX, including new investment from BVF Partners, Lightspeed Venture Partners (Lightspeed) and Perceptive Advisors
- Three first-in-class ADC assets funded through clinical proof of concept
London UK, 21 May 2024 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing to fund the development of its pipeline of differentiated ADCs. The financing was led by TCGX with participation from other new investors BVF Partners, Lightspeed and Perceptive Advisors, alongside existing investors Atlas Venture, Brandon Capital, Forbion, and Research Corporation Technologies.
